Virus–host interplay in hepatitis B virus infection and epigenetic treatment strategies
ABSTRACT: Worldwide, chronic hepatitis B virus (HBV) infection is a major health problem and no cure exists. Importantly, hepatocyte intrusion by HBV particles results in a complex deregulation of both viral and host cellular genetic and epigenetic processes. Among the attempts to develop novel ther...
- Autores:
-
Hensel, Kai
Rendón Londoño, Julio Cesar
Navas Navas, María Cristina
Rots, Marianne
Postberg, Jan
- Tipo de recurso:
- Review article
- Fecha de publicación:
- 2017
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/23347
- Acceso en línea:
- http://hdl.handle.net/10495/23347
- Palabra clave:
- Sistemas CRISPR-Cas
CRISPR-Cas Systems
Metilación de ADN
DNA Methylation
Epigenoma
Epigenome
Virus de la Hepatitis B
Hepatitis B virus
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by-nc-nd/2.5/co/
| id |
UDEA2_ece52f8a5195d2d411f7eadd2c62b54a |
|---|---|
| oai_identifier_str |
oai:bibliotecadigital.udea.edu.co:10495/23347 |
| network_acronym_str |
UDEA2 |
| network_name_str |
Repositorio UdeA |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Virus–host interplay in hepatitis B virus infection and epigenetic treatment strategies |
| title |
Virus–host interplay in hepatitis B virus infection and epigenetic treatment strategies |
| spellingShingle |
Virus–host interplay in hepatitis B virus infection and epigenetic treatment strategies Sistemas CRISPR-Cas CRISPR-Cas Systems Metilación de ADN DNA Methylation Epigenoma Epigenome Virus de la Hepatitis B Hepatitis B virus |
| title_short |
Virus–host interplay in hepatitis B virus infection and epigenetic treatment strategies |
| title_full |
Virus–host interplay in hepatitis B virus infection and epigenetic treatment strategies |
| title_fullStr |
Virus–host interplay in hepatitis B virus infection and epigenetic treatment strategies |
| title_full_unstemmed |
Virus–host interplay in hepatitis B virus infection and epigenetic treatment strategies |
| title_sort |
Virus–host interplay in hepatitis B virus infection and epigenetic treatment strategies |
| dc.creator.fl_str_mv |
Hensel, Kai Rendón Londoño, Julio Cesar Navas Navas, María Cristina Rots, Marianne Postberg, Jan |
| dc.contributor.author.none.fl_str_mv |
Hensel, Kai Rendón Londoño, Julio Cesar Navas Navas, María Cristina Rots, Marianne Postberg, Jan |
| dc.subject.decs.none.fl_str_mv |
Sistemas CRISPR-Cas CRISPR-Cas Systems Metilación de ADN DNA Methylation Epigenoma Epigenome Virus de la Hepatitis B Hepatitis B virus |
| topic |
Sistemas CRISPR-Cas CRISPR-Cas Systems Metilación de ADN DNA Methylation Epigenoma Epigenome Virus de la Hepatitis B Hepatitis B virus |
| description |
ABSTRACT: Worldwide, chronic hepatitis B virus (HBV) infection is a major health problem and no cure exists. Importantly, hepatocyte intrusion by HBV particles results in a complex deregulation of both viral and host cellular genetic and epigenetic processes. Among the attempts to develop novel therapeutic approaches against HBV infection, several options targeting the epigenomic regulation of HBV replication are gaining attention. These include the experimental treatment with ‘epidrugs’. Moreover, as a targeted approach, the principle of ‘epigenetic editing’ recently is being exploited to control viral replication. Silencing of HBV by specific rewriting of epigenetic marks might diminish viral replication, viremia, and infectivity, even- tually controlling the disease and its complications. Additionally, epigenetic editing can be used as an experimental tool to increase our limited understanding regarding the role of epigenetic modifications in viral infections. Aiming for permanent epigenetic reprogramming of the viral genome without unspecific side effects, this breakthrough may pave the roads for an ambitious technological pursuit: to start designing a curative approach utilizing manipulative molecular therapies for viral infections in vivo. |
| publishDate |
2017 |
| dc.date.issued.none.fl_str_mv |
2017 |
| dc.date.accessioned.none.fl_str_mv |
2021-10-21T15:53:13Z |
| dc.date.available.none.fl_str_mv |
2021-10-21T15:53:13Z |
| dc.type.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.hasversion.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_dcae04bc |
| dc.type.redcol.spa.fl_str_mv |
https://purl.org/redcol/resource_type/ARTREV |
| dc.type.local.spa.fl_str_mv |
Artículo de revisión |
| format |
http://purl.org/coar/resource_type/c_dcae04bc |
| status_str |
publishedVersion |
| dc.identifier.issn.none.fl_str_mv |
1742-464X 10.1111/febs.14094 |
| dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/10495/23347 |
| dc.identifier.eissn.none.fl_str_mv |
1742-4658 |
| identifier_str_mv |
1742-464X 10.1111/febs.14094 1742-4658 |
| url |
http://hdl.handle.net/10495/23347 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.ispartofjournalabbrev.spa.fl_str_mv |
FEBS. J. |
| dc.rights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ |
| dc.rights.accessrights.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.creativecommons.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.format.extent.spa.fl_str_mv |
23 |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
Wiley Federation of European Biochemical Societies |
| dc.publisher.group.spa.fl_str_mv |
Grupo de Gastrohepatología |
| dc.publisher.place.spa.fl_str_mv |
Oxford, Inglaterra |
| institution |
Universidad de Antioquia |
| bitstream.url.fl_str_mv |
http://bibliotecadigital.udea.edu.co/bitstream/10495/23347/2/license_rdf http://bibliotecadigital.udea.edu.co/bitstream/10495/23347/3/license.txt http://bibliotecadigital.udea.edu.co/bitstream/10495/23347/1/JulioRendon_2017_VirusInfectionStrategies.pdf |
| bitstream.checksum.fl_str_mv |
b88b088d9957e670ce3b3fbe2eedbc13 8a4605be74aa9ea9d79846c1fba20a33 06b72cc4bbcee52e6c18cfad39dfb5dd |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional Universidad de Antioquia |
| repository.mail.fl_str_mv |
andres.perez@udea.edu.co |
| _version_ |
1812173218001190912 |
| spelling |
Hensel, KaiRendón Londoño, Julio CesarNavas Navas, María CristinaRots, MariannePostberg, Jan2021-10-21T15:53:13Z2021-10-21T15:53:13Z20171742-464X10.1111/febs.14094http://hdl.handle.net/10495/233471742-4658ABSTRACT: Worldwide, chronic hepatitis B virus (HBV) infection is a major health problem and no cure exists. Importantly, hepatocyte intrusion by HBV particles results in a complex deregulation of both viral and host cellular genetic and epigenetic processes. Among the attempts to develop novel therapeutic approaches against HBV infection, several options targeting the epigenomic regulation of HBV replication are gaining attention. These include the experimental treatment with ‘epidrugs’. Moreover, as a targeted approach, the principle of ‘epigenetic editing’ recently is being exploited to control viral replication. Silencing of HBV by specific rewriting of epigenetic marks might diminish viral replication, viremia, and infectivity, even- tually controlling the disease and its complications. Additionally, epigenetic editing can be used as an experimental tool to increase our limited understanding regarding the role of epigenetic modifications in viral infections. Aiming for permanent epigenetic reprogramming of the viral genome without unspecific side effects, this breakthrough may pave the roads for an ambitious technological pursuit: to start designing a curative approach utilizing manipulative molecular therapies for viral infections in vivo.COL002415923application/pdfengWileyFederation of European Biochemical SocietiesGrupo de GastrohepatologíaOxford, Inglaterrainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_dcae04bchttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARTREVArtículo de revisiónhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/http://purl.org/coar/access_right/c_abf2https://creativecommons.org/licenses/by-nc-nd/4.0/Virus–host interplay in hepatitis B virus infection and epigenetic treatment strategiesSistemas CRISPR-CasCRISPR-Cas SystemsMetilación de ADNDNA MethylationEpigenomaEpigenomeVirus de la Hepatitis BHepatitis B virusFEBS. J.The Febs Journal35503572284CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8823http://bibliotecadigital.udea.edu.co/bitstream/10495/23347/2/license_rdfb88b088d9957e670ce3b3fbe2eedbc13MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://bibliotecadigital.udea.edu.co/bitstream/10495/23347/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD53ORIGINALJulioRendon_2017_VirusInfectionStrategies.pdfJulioRendon_2017_VirusInfectionStrategies.pdfArtículo de revisiónapplication/pdf1131773http://bibliotecadigital.udea.edu.co/bitstream/10495/23347/1/JulioRendon_2017_VirusInfectionStrategies.pdf06b72cc4bbcee52e6c18cfad39dfb5ddMD5110495/23347oai:bibliotecadigital.udea.edu.co:10495/233472021-10-21 10:53:13.686Repositorio Institucional Universidad de Antioquiaandres.perez@udea.edu.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 |